Sales from the Accelerator Lab in the quarter were mostly from recurring customers, with a 36% growth. The strategy of combining consumables and services resulted in 80% recurring revenues. Diagnostics' contribution to top-line growth depends on patient utilization of therapies like Lambi and Kuma.